FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003460520> ?p ?o ?g. }

• W3003460520 endingPage "392" @default.
• W3003460520 startingPage "379" @default.
• W3003460520 abstract "Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). Our objective was to compare the incidence rates (IRs) of adverse events in tofacitinib clinical trials and real-world observational data for alternative treatments. The tofacitinib “dose-comparison cohort” included months 0–12 of two phase III studies (tofacitinib 5 [n = 238] and 10 [n = 236] mg twice daily [BID]); the “all-tofacitinib comparison cohort” (n = 783) included two phase III and one ongoing long-term extension study (data cutoff May 2016). An “observational comparison cohort” (n = 5799) comprised patients initiating a conventional synthetic disease-modifying antirheumatic drug (DMARD), biologic DMARD, or apremilast in the US Truven MarketScan database from 2010 to 2015. IRs for serious infections (SIEs; requiring hospitalization), herpes zoster (HZ), malignancies (excluding non-melanoma skin cancer [NMSC]), NMSC, and major adverse cardiovascular events (MACE) across cohorts were qualitatively compared. IRs (patients with events/100 patient-years) for SIEs were similar between the tofacitinib dose-comparison cohort (5 mg BID: 1.3; 10 mg BID: 2.0) and the observational comparison cohort (1.1–7.9; treatment dependent). The tofacitinib dose-comparison cohort had a higher rate of HZ (5 mg BID: 2.0; 10 mg BID: 2.7) than did the observational comparison cohort (0.8–2.0). IRs for NMSC were generally lower in the all-tofacitinib comparison cohort (0.5) than in the observational comparison cohort (0.4–6.0). IRs for MACE, malignancies excluding NMSC, and NMSC were similar between cohorts. In patients with PsA, tofacitinib had a safety profile similar to that of other systemic therapies in real-world settings, except for the risk of HZ, a known risk of tofacitinib. ClinicalTrials.gov: NCT01877668; NCT01882439; NCT01976364." @default.
• W3003460520 created "2020-02-07" @default.
• W3003460520 creator A5000754711 @default.
• W3003460520 creator A5006070255 @default.
• W3003460520 creator A5008763926 @default.
• W3003460520 creator A5010870801 @default.
• W3003460520 creator A5017740190 @default.
• W3003460520 creator A5027752564 @default.
• W3003460520 creator A5028501963 @default.
• W3003460520 creator A5034581240 @default.
• W3003460520 creator A5048376276 @default.
• W3003460520 creator A5073833664 @default.
• W3003460520 creator A5075200726 @default.
• W3003460520 creator A5075536702 @default.
• W3003460520 creator A5077643606 @default.
• W3003460520 creator A5082474412 @default.
• W3003460520 creator A5084902943 @default.
• W3003460520 date "2020-01-31" @default.
• W3003460520 modified "2023-10-17" @default.
• W3003460520 title "An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data" @default.
• W3003460520 cites W117283996 @default.
• W3003460520 cites W1598733992 @default.
• W3003460520 cites W1835690873 @default.
• W3003460520 cites W1892676932 @default.
• W3003460520 cites W1925361523 @default.
• W3003460520 cites W1977156691 @default.
• W3003460520 cites W1984883552 @default.
• W3003460520 cites W1991688187 @default.
• W3003460520 cites W1991973624 @default.
• W3003460520 cites W1992384494 @default.
• W3003460520 cites W2013623666 @default.
• W3003460520 cites W2025506838 @default.
• W3003460520 cites W2065630419 @default.
• W3003460520 cites W2076859422 @default.
• W3003460520 cites W2083707884 @default.
• W3003460520 cites W2099706116 @default.
• W3003460520 cites W2101598919 @default.
• W3003460520 cites W2111624359 @default.
• W3003460520 cites W2120045958 @default.
• W3003460520 cites W2125078612 @default.
• W3003460520 cites W2130829606 @default.
• W3003460520 cites W2131254861 @default.
• W3003460520 cites W2132226325 @default.
• W3003460520 cites W2133633410 @default.
• W3003460520 cites W2133701923 @default.
• W3003460520 cites W2147514808 @default.
• W3003460520 cites W2152350812 @default.
• W3003460520 cites W2163184895 @default.
• W3003460520 cites W2167609288 @default.
• W3003460520 cites W2169389668 @default.
• W3003460520 cites W2194197257 @default.
• W3003460520 cites W2272132418 @default.
• W3003460520 cites W2283622962 @default.
• W3003460520 cites W2343952032 @default.
• W3003460520 cites W2416365354 @default.
• W3003460520 cites W2503219031 @default.
• W3003460520 cites W2543549509 @default.
• W3003460520 cites W2548897914 @default.
• W3003460520 cites W2559865294 @default.
• W3003460520 cites W2584430503 @default.
• W3003460520 cites W2734390848 @default.
• W3003460520 cites W2748091531 @default.
• W3003460520 cites W2766717228 @default.
• W3003460520 cites W2766846920 @default.
• W3003460520 cites W2778484302 @default.
• W3003460520 cites W2808333862 @default.
• W3003460520 cites W4236700223 @default.
• W3003460520 doi "https://doi.org/10.1007/s40264-020-00904-9" @default.
• W3003460520 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7105422" @default.
• W3003460520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32006348" @default.
• W3003460520 hasPublicationYear "2020" @default.
• W3003460520 type Work @default.
• W3003460520 sameAs 3003460520 @default.
• W3003460520 citedByCount "26" @default.
• W3003460520 countsByYear W30034605202020 @default.
• W3003460520 countsByYear W30034605202021 @default.
• W3003460520 countsByYear W30034605202022 @default.
• W3003460520 countsByYear W30034605202023 @default.
• W3003460520 crossrefType "journal-article" @default.
• W3003460520 hasAuthorship W3003460520A5000754711 @default.
• W3003460520 hasAuthorship W3003460520A5006070255 @default.
• W3003460520 hasAuthorship W3003460520A5008763926 @default.
• W3003460520 hasAuthorship W3003460520A5010870801 @default.
• W3003460520 hasAuthorship W3003460520A5017740190 @default.
• W3003460520 hasAuthorship W3003460520A5027752564 @default.
• W3003460520 hasAuthorship W3003460520A5028501963 @default.
• W3003460520 hasAuthorship W3003460520A5034581240 @default.
• W3003460520 hasAuthorship W3003460520A5048376276 @default.
• W3003460520 hasAuthorship W3003460520A5073833664 @default.
• W3003460520 hasAuthorship W3003460520A5075200726 @default.
• W3003460520 hasAuthorship W3003460520A5075536702 @default.
• W3003460520 hasAuthorship W3003460520A5077643606 @default.
• W3003460520 hasAuthorship W3003460520A5082474412 @default.
• W3003460520 hasAuthorship W3003460520A5084902943 @default.
• W3003460520 hasBestOaLocation W30034605201 @default.
• W3003460520 hasConcept C121332964 @default.
• W3003460520 hasConcept C126322002 @default.
• W3003460520 hasConcept C16005928 @default.

• next